Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

On Friday evening, Sage said that Biogen had offered to buy the roughly 90% of Sage it does not already own for $469 million, ...

Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to ...

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

The collaboration between Biogen and Sage dates to 2020. Biogen committed $1.5 billion up front to begin the R&D alliance focused on depression and movement disorders. Results have been ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) recently received an unsolicited bid proposal from Biogen Inc. to be purchased at around $7.22 per share.This represents a 30% premium to the price of the ...